65 related articles for article (PubMed ID: 26474434)
1. Prognostic Value of Somatostatin Receptor Subtypes in Pancreatic Neuroendocrine Tumors.
Song KB; Kim SC; Kim JH; Seo DW; Hong SM; Park KM; Hwang DW; Lee JH; Lee YJ
Pancreas; 2016 Feb; 45(2):187-92. PubMed ID: 26474434
[TBL] [Abstract][Full Text] [Related]
2. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies.
Kulaksiz H; Eissele R; Rössler D; Schulz S; Höllt V; Cetin Y; Arnold R
Gut; 2002 Jan; 50(1):52-60. PubMed ID: 11772967
[TBL] [Abstract][Full Text] [Related]
3. Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis.
Cigrovski Berkovic M; Coppola A; Sesa V; Mrzljak A; Lai Q
World J Gastroenterol; 2024 Feb; 30(7):759-769. PubMed ID: 38515954
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor staining in FFPE sections using a ligand derivative dye as an alternative to immunostaining.
Hasegawa K; Kudoh S; Ito T
PLoS One; 2017; 12(2):e0172030. PubMed ID: 28182792
[TBL] [Abstract][Full Text] [Related]
5. Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation.
Pisarek H; Stepień T; Kubiak R; Borkowska E; Pawlikowski M
Thyroid Res; 2009 Jan; 2(1):1. PubMed ID: 19173713
[TBL] [Abstract][Full Text] [Related]
6. SSTR5 P335L monoclonal antibody differentiates pancreatic neuroendocrine neuroplasms with different SSTR5 genotypes.
Zhou G; Gingras MC; Liu SH; Sanchez R; Edwards D; Dawson D; Christensen K; Paganelli G; Gibbs R; Fisher W; Brunicardi FC
Surgery; 2011 Dec; 150(6):1136-42. PubMed ID: 22136833
[TBL] [Abstract][Full Text] [Related]
7. Translational Potential of a Contrast Agent for FGS Applications in pNETs.
AghaAmiri S; Estrella JS; Vargas SH; Hurd MW; Ghosh SC; Azhdarinia A; Ikoma N
Mol Imaging Biol; 2024 Apr; 26(2):191-194. PubMed ID: 38267640
[No Abstract] [Full Text] [Related]
8. Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets.
Maharjan CK; Ear PH; Tran CG; Howe JR; Chandrasekharan C; Quelle DE
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680266
[TBL] [Abstract][Full Text] [Related]
9. Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome?
Dalm SU; de Jong M
EJNMMI Radiopharm Chem; 2017; 2(1):11. PubMed ID: 29503852
[No Abstract] [Full Text] [Related]
10. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.
Tang LH; Untch BR; Reidy DL; O'Reilly E; Dhall D; Jih L; Basturk O; Allen PJ; Klimstra DS
Clin Cancer Res; 2016 Feb; 22(4):1011-7. PubMed ID: 26482044
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors.
Wang Y; Wang W; Jin K; Fang C; Lin Y; Xue L; Feng S; Zhou Z; Shao C; Chen M; Yu X; Chen J
Oncol Lett; 2017 Mar; 13(3):1165-1174. PubMed ID: 28454229
[TBL] [Abstract][Full Text] [Related]
12. Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors.
Qian ZR; Li T; Ter-Minassian M; Yang J; Chan JA; Brais LK; Masugi Y; Thiaglingam A; Brooks N; Nishihara R; Bonnemarie M; Masuda A; Inamura K; Kim SA; Mima K; Sukawa Y; Dou R; Lin X; Christiani DC; Schmidlin F; Fuchs CS; Mahmood U; Ogino S; Kulke MH
Pancreas; 2016 Nov; 45(10):1386-1393. PubMed ID: 27622342
[TBL] [Abstract][Full Text] [Related]
13. Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?
van Adrichem RC; Kamp K; van Deurzen CH; Biermann K; Feelders RA; Franssen GJ; Kwekkeboom DJ; Hofland LJ; de Herder WW
Neuroendocrinology; 2016; 103(5):560-6. PubMed ID: 26536001
[TBL] [Abstract][Full Text] [Related]
14. Clinical Features and Prognosis of Resectable Primary Colorectal Signet-Ring Cell Carcinoma.
Lee HS; Soh JS; Lee S; Bae JH; Kim KJ; Ye BD; Byeon JS; Myung SJ; Yang SK; Kim SA; Park YS; Lim SB; Kim JC; Yu CS; Yang DH
Intest Res; 2015 Oct; 13(4):332-8. PubMed ID: 26576139
[TBL] [Abstract][Full Text] [Related]
15. Resection versus expectant management of small incidentally discovered nonfunctional pancreatic neuroendocrine tumors.
Rosenberg AM; Friedmann P; Del Rivero J; Libutti SK; Laird AM
Surgery; 2016 Jan; 159(1):302-9. PubMed ID: 26547726
[TBL] [Abstract][Full Text] [Related]
16. Octreotide in combination with AT-101 induces cytotoxicity and apoptosis through up-regulation of somatostatin receptors 2 and 5 in DU-145 prostate cancer cells.
Degirmenci M; Erdogan AP; Bulut G; Atmaca H; Uzunoglu S; Karaca B; Karabulut B; Uslu R
Tumour Biol; 2016 Apr; 37(4):4939-44. PubMed ID: 26531719
[TBL] [Abstract][Full Text] [Related]
17. Laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: results of a multicenter cohort study on 196 patients.
Sahakyan MA; Kazaryan AM; Rawashdeh M; Fuks D; Shmavonyan M; Haugvik SP; Labori KJ; Buanes T; Røsok BI; Ignjatovic D; Abu Hilal M; Gayet B; Kim SC; Edwin B
Surg Endosc; 2016 Aug; 30(8):3409-18. PubMed ID: 26514135
[TBL] [Abstract][Full Text] [Related]
18. SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin.
Park SJ; Kim SM; Moon JH; Kim JH; Shin JS; Hong SW; Shin YJ; Lee DH; Lee EY; Hwang IY; Kim JE; Kim KP; Hong YS; Lee WK; Choi EK; Lee JS; Jin DH; Kim TW
Tumour Biol; 2016 Apr; 37(4):4323-30. PubMed ID: 26493999
[TBL] [Abstract][Full Text] [Related]
19. Utility of indocyanine-green fluorescent imaging during robot-assisted sphincter-saving surgery on rectal cancer patients.
Kim JC; Lee JL; Yoon YS; Alotaibi AM; Kim J
Int J Med Robot; 2016 Dec; 12(4):710-717. PubMed ID: 26486376
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly.
Heck A; Emblem KE; Casar-Borota O; Bollerslev J; Ringstad G
Endocrine; 2016 May; 52(2):333-43. PubMed ID: 26475495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
